论文部分内容阅读
目的:研究Aurora-A、B、C(AUR-A、B、C)基因mRNA在急性白血病中的表达情况及其与临床指标的相关性。方法:采用荧光定量PCR检测73例初诊急性白血病(AL)患者(初诊组)、20例化疗完全缓解急性白血病患者(缓解组)和骨髓单个核细胞中AUR-A、B、C mRNA表达水平,14例健康志愿者作为对照(健康组),并分析它们分别在不同分组中的表达性差异,与临床指标的相关性及AUR-A、B、C mRNA表达水平之间的相关性。结果:AURA、B、C mRNA表达在初诊组均高于健康组和缓解组(P<0.01),健康组和缓解组3种基因mRNA表达水平差异均无统计学意义(P>0.05),AUR-A、B、C 3种基因mRNA表达水平在急性淋巴细胞白血病(ALL)组均高于急性髓系白血病(AML)组(P<0.01);AUR-A、B、C mRNA表达在高危组均高于低危组(P<0.05),在高危组与中危组及中危组与低危组之间差异无统计学意义(P>0.05);AUR-A、B、C表达在CD34、CD71、CD56阴性组和阳性组差异无统计学意义(P>0.05),在不同性别、染色体、1疗程化疗是否缓解分组中差异无统计学意义(P>0.05)。73例初诊AL患者中,AUR-A mRNA表达水平与初诊乳酸脱氢酶(LDH)水平和危险分层呈显著正相关(r=0.279,P=0.017;r=0.314,P=0.007);AUR-B与初诊LDH水平和危险分层呈显著正相关(r=0.277,P=0.018;r=0.349,P=0.002),AUR-A、B均与年龄、初诊白细胞(WBC)水平、初诊骨髓幼稚细胞比例和1疗程是否缓解无显著相关性;AUR-C表达水平与初诊白细胞水平、初诊LDH水平和危险分层显著正相关(r=0.263,P=0.025;r=0.348,P=0.003;r=0.376,P=0.001),与年龄显著负相关(r=-0.241,P=0.040),而与初诊骨髓中幼稚细胞比例和1疗程是否缓解无显著相关性;AUR-A和B(r=0.444,P=0.000)、AUR-B和C(r=0.763,P=0.000)、AUR-A和C(r=0.616,P=0.000)mRNA表达水平均呈显著正相关。结论:AUR-A、B、C mRNA在初诊急性白血病患者中高表达并且三者间表达水平显著正相关,其高表达与白血病类型、危险分层、初诊白细胞和乳酸脱氢酶水平等指标相关,均可作为预后指标和潜在治疗靶点
Objective: To investigate the expression of Aurora-A, B, C (AUR-A, B, C) mRNA in acute leukemia and its correlation with clinical parameters. Methods: The mRNA expression levels of AUR-A, B and C in 73 newly diagnosed acute leukemia (AL) patients, 20 patients with complete remission acute leukemia (remission group) and bone marrow mononuclear cells were detected by real-time PCR. A total of 14 healthy volunteers were selected as control group (healthy group), and their differences in expression among different groups were analyzed. The correlations with clinical indicators and the expression of AUR-A, B and C mRNA were also analyzed. Results: The mRNA expression of AURA, B and C in the newly diagnosed group was significantly higher than that in the healthy group and remission group (P <0.01). There was no significant difference in mRNA expression of AURA, B and C between the two groups (P> 0.05) The mRNA expression levels of -A, B and C were higher in acute lymphoblastic leukemia (ALL) group than in AML group (P <0.01). The expression of AUR-A, B and C mRNA in high- (P <0.05). There was no significant difference between high-risk group and intermediate-risk group and intermediate-risk group and low-risk group (P> 0.05). The expression of AUR-A, B and C in CD34 There was no significant difference between the negative group and the positive group of CD71, CD56 and positive group (P> 0.05). There was a significant positive correlation between the expression level of AUR-A mRNA and the level of LDH and the risk stratification in newly diagnosed AL patients (r = 0.279, P = 0.017; r = 0.314, P = 0.007) B was positively correlated with newly diagnosed LDH level and risk stratification (r = 0.277, P = 0.018; r = 0.349, P = 0.002). AUR-A and B were significantly correlated with age, WBC level, There was no significant correlation between the proportion of immature cells and the remission of one course of treatment. The expression level of AUR-C was positively correlated with newly diagnosed leukocytes, newly diagnosed LDH and risk stratification (r = 0.263, P = 0.025; r = 0.348, (r = -0.241, P = 0.040), but there was no significant correlation with the proportion of immature cells in the newly diagnosed bone marrow and the remission of a course of treatment. The AUR-A and B (r = (P = 0.000), AUR-B and C (r = 0.763, P = 0.000), AUR-A and C (r = 0.616, P = 0.000) CONCLUSIONS: AUR-A, B and C mRNA are highly expressed in newly diagnosed acute leukemia patients and the expression of AUR-A, B and C is significantly and positively correlated with each other. The high expression of AUR-A, B and C mRNA is correlated with leukemia type, risk stratification, newly diagnosed leukocyte and lactate dehydrogenase, Can be used as a prognostic indicator and potential therapeutic targets